Last reviewed · How we verify

NCT04374370

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

NO LONGER AVAILABLE Last updated 6 May 2021
What this trial tests

trial testing SARSCoV2 Convalescent Plasma in COVID. No longer available.

Quick facts

Lead sponsorAdventHealth
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

AdventHealth — full company profile →

Who can join

Adults 6 to 99, any sex, with COVID or SARSCoV2 Convalescent Plasma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Convalescent plasma has been administered to treat different infectious diseases previously with some success. There is currently no approved and proven treatment options available for the novel coronavirus disease (COVID-19 virus). Some early data has shown a potential benefit in treating hospitalized patients who have tested positive for COVID-19 with convalescent plasma infusions of fresh plasma donated by fully recovered COVID-19 patients. The antibodies present in the recovered patients' plasma may be of benefit in helping critically ill and infected patients recover from the COVID-19 virus.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V, Chai KL, Valk SJ, Doree C, et al · · 2020 · cited 148× · PMID 32648959 · DOI 10.1002/14651858.cd013600.pub2
  2. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
  3. Convalescent Plasma Therapy for COVID-19: State of the Art.
    Focosi D, Anderson AO, Tang JW, Tuccori M. · · 2020 · cited 88× · PMID 32792417 · DOI 10.1128/cmr.00072-20
  4. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies.
    Cotugno N, Ruggiero A, Bonfante F, Petrara MR, et al · · 2021 · cited 49× · PMID 33730580 · DOI 10.1016/j.celrep.2021.108852
  5. Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
    Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063
  6. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments.
    Goodarzi P, Mahdavi F, Mirzaei R, Hasanvand H, et al · · 2020 · cited 26× · PMID 32795893 · DOI 10.1016/j.intimp.2020.106885
  7. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
  8. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6

Verify or expand the search:

Other recruiting trials for COVID

Currently open trials in the same condition.

Other AdventHealth trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing